Search Within

Dana Elizabeth Rathkopf

  1. "Hematology-Oncology Fellows"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (2)
Groups
  1. Department of Medicine (6)
  2. Genitourinary Oncology Service (6)
  3. Hematology-Oncology Fellows (6)
  4. Solid Tumor Oncology Division (6)
  5. Department of Pathology and Laboratory Medicine (4)
  6. GME, Medicine (4)

More Groups

People
  1. Jimmy Zhao (4)
  2. Brett Carver (3)
  3. Howard Scher (3)
  4. Wassim Abida (3)
  5. Anuradha Gopalan (2)
  6. Brooke Decker (2)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2022 (1)
  4. 2021 (1)
  5. 2020 (1)
Publications
  1. Annals of Oncology (1)
  2. British Journal of Cancer (1)
  3. Cancer Research (1)
  4. Journal of Urology (1)
  5. Nature Medicine (1)
  6. Proceedings of the National Academy of Sciences of the United States of America (1)
Publishers
  1. Nature Publishing Group (2)
  2. American Association for Cancer Research (1)
  3. Elsevier Science, Inc. (1)
  4. National Academy of Sciences (1)
  5. Oxford University Press (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies
    Journal Article

    Zaidi, S.; Park, J.; Chan, J. M.; Roudier, M. P.; Zhao, J. L.; Gopalan, A.; Wadosky, K. M.; Patel, R. A.; Sayar, E.; Karthaus, W. R.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2024)

    Fulltext@MSK | Save
  • Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
    Journal Article

    Zhao, J. L.; Antonarakis, E. S.; Cheng, H. H.; George, D. J.; Aggarwal, R.; Riedel, E.; Sumiyoshi, T.; Schonhoft, J. D.; Anderson, A.; Mao, N.; more...
    British Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade
    Journal Article

    Harrold, E. C.; Foote, M. B.; Rousseau, B.; Walch, H.; Kemel, Y.; Richards, A. L.; Keane, F.; Cercek, A.; Yaeger, R.; Rathkopf, D.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Dermatological adverse events in prostate cancer patients treated with the androgen receptor inhibitor apalutamide
    Journal Article

    Pan, A.; Reingold, R. E.; Zhao, J. L.; Moy, A.; Kraehenbuehl, L.; Dranitsaris, G.; McBride, S. M.; Scher, H. I.; Kollmeier, M. A.; Xiao, H.; more...
    Journal of Urology (2022)

    Fulltext@MSK | Save
  • A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Zhao, J. L.; Antonarakis, S.; Cheng, H.; George, D. J.; Aggarwal, R. R.; Abida, W.; Decker, B.; Smart-Curley, T.; Schonhoft, J.; Anderson, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Identification of the cells of origin and tumor heterogeneity in neuroendocrine prostate cancer (NEPC) by single-cell analysis
    Meeting Abstract

    Zhao, J. L.; Zaidi, S.; Chan, J.; Wadosky, K.; Karthaus, W.; Choi, D.; Agudelo Rivera, A.; Gopalan, A.; Rathkopf, D.; Carver, B.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save